Medicine Matters rheumatology

Welcome

We provide news, expert interviews, and educational resources to help you keep up with the latest developments in rheumatology

Learn more

Conference coverage

ACR Convergence 2022

Medicine Matters rheumatology is covering the ACR Convergence 2022 meeting, bringing you news on the latest research. Browse now

News

Dapagliflozin may warrant further investigation for SLE

Dapagliflozin deserves further study as an add-on therapy for reducing renal and cardiovascular risk in patients with systemic lupus erythematosus, suggest preliminary trial findings. Read more

Have the ORAL Surveillance results changed rheumatology practice?

Following publication of the ORAL Surveillance trial, Richard Conway and Kevin Winthrop discuss the impact of the findings on JAK inhibitor prescribing, how regulatory recommendations compare in Europe and the USA, and whether the risks seen with tofacitinib represent a class effect.

Anti-SSSCA1 positivity tied to cancer risk in SSc patients

The metabolic syndrome may influence the risk for gout

Treatment goals in late-onset RA should match those for younger patients

LOUiSSe study shows remibrutinib efficacy in Sjögren’s syndrome

Abortion restrictions impede methotrexate access for some rheumatology patients

A Great Debate: To treat or not to treat in pre-RA?

View all latest news

IN FOCUS | JAK inhibitors

18-10-2022 | Psoriatic arthritis | News

Support for JAK inhibitors as ‘drug of choice’ for patients with PsA and significant joint disease

JAK inhibitors show promise for the treatment of moderate-to-severe psoriasis and psoriatic arthritis, finds a systematic review and meta-analysis of more than 6000 patients.

JUVE-BASIS: Support for baricitinib in juvenile arthritis

ASAS, EULAR issue updated recommendations on axSpA management

Support for JAK inhibitors as ‘drug of choice’ for patients with PsA and significant joint disease

Study identifies sex differences in RA remission rates

EMA recommends approval of upadacitinib for nonradiographic axSpA

Targeted therapy not linked to serious infection risk in older people with RA

IN FOCUS | COVID-19 & rheumatic disease

24-10-2022 | COVID-19 | News

Prophylactic antivirals may help prevent symptomatic COVID-19 in rituximab-treated patients

Pre-exposure prophylaxis with tixagevimab and cilgavimab may be an effective strategy to prevent symptomatic SARS-CoV-2 infection among people with rheumatic diseases treated with rituximab, suggest findings from a real-world study.

IN FOCUS | Inflammatory arthritis

28-11-2022 | Rheumatoid arthritis | News

Treatment goals in late-onset RA should match those for younger patients

People with late-onset rheumatoid arthritis have a similar likelihood of achieving remission as those with earlier-onset disease, indicating that treatment goals should be the same in both populations, researchers report.

The metabolic syndrome may influence the risk for gout

Treatment goals in late-onset RA should match those for younger patients

A Great Debate: To treat or not to treat in pre-RA?

Secukinumab comparable to adalimumab biosimilar in axSpA

PD-1 receptor agonist may represent a novel treatment for patients with RA

Pre-eclampsia warning for women with PsA or RA

IN FOCUS | Gout and crystal arthropathies

04-08-2022 | Gout | News

Gout flares linked to temporary increase in cardiovascular risk

Gout flares are associated with an increased risk for cardiovascular events in the following 120 days, study findings suggest.

The metabolic syndrome may influence the risk for gout

SGLT2 inhibitors linked to lower gout risk than DPP-4 inhibitors

Local environment impacts recurrent hospitalization risk in rheumatic disease

Gout risk factor prevalence may explain increased rates among Black Americans

Gout flares linked to temporary increase in cardiovascular risk

Study highlights sex-specific CVD risks in men with gout

IN FOCUS | Lupus

14-11-2022 | ACR 2022 | Conference coverage | News

Phase 3 trial supports add-on telitacicept for SLE

Addition of the recombinant fusion protein telitacicept to standard care may reduce disease activity and is well tolerated in people with systemic lupus erythematosus, research suggests.

Phase 3 trial supports add-on telitacicept for SLE

Achieving LLDAS tied to reduced mortality risk in SLE

Dapagliflozin may warrant further investigation for SLE

Reduced-dose hydroxychloroquine linked to higher flare risk in SLE

Local environment impacts recurrent hospitalization risk in rheumatic disease

Male sex, older age risk factors for acute kidney abnormalities in childhood SLE

Stay informed with Medicine Matters

Get the latest developments in rheumatology delivered straight to your inbox

Image Credits

Medicine Matters branded image/© Springer Healthcare, ACR Convergence 2022, Close up young woman taking pill, holding water glass/© fizkes / stock.adobe.com, Richard Conway and Kevin Winthrop, Simple 3d scene representing arrows, that hit targets with blackvision./© ShadeON / Getty images / iStock, Debate (concept)/© Andrii Yalanskyi / stock.adobe.com, Close up of young woman taking in pill/© kieferpix / stock.adobe.com, Doctor holds a two puzzle pieces with gender symbols/© wladimir1804 / stock.adobe.com, Magnifying glass and laptop/© Michail_Petrov-96 / Getty Images / iStock, Doctor with stethoscope and glowing coronavirus cell - medicine and innovation concept./© Floriana / Getty Images / iStock, Close up of a teenage girl wearing a mask being vaccinated/© © klavdiyav / stock.adobe.com, Covid-19 antigen self-tests positive, buffer bottles and thin black-rimmed glasses/© Kira / stock.adobe.com, IV drip/© © Trsakaoe / stock.adobe.com, Doctor and calculator/© nito / stock.adobe.com, Man with painful and swollen right foot due to gout inflammation/© ThamKC / stock.adobe.com, Febuxostat and CV risk signpost image/© hriana / stock.adobe.com, Close up of medical disposable syringe and vial/© Kuzmik_A / Getty Images / iStock, Anifrolumab for the treatment of lupus/© ustas / stock.adobe.com, New Content Item/© bloomicon / stock.adobe.com